{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:23:05Z","timestamp":1778325785688,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.urolonc.2024.09.020","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T21:04:29Z","timestamp":1729026269000},"page":"329.e1-329.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan"],"prefix":"10.1016","volume":"43","author":[{"given":"Shotaro","family":"Yasuoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotoba","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0737","authenticated-orcid":false,"given":"Toshiki","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Uenaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.09.020_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ctrv.2007.12.006","article-title":"Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium","volume":"34","author":"Vaughn","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0003","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/14737140.2023.2265572","article-title":"Immunotherapy in urothelial cancer: current status and future directions","volume":"23","author":"Piombino","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0004","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0005","doi-asserted-by":"crossref","first-page":"195.e1","DOI":"10.1016\/j.urolonc.2021.11.014","article-title":"Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States","volume":"40","author":"Geynisman","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0006","doi-asserted-by":"crossref","first-page":"357.e11","DOI":"10.1016\/j.urolonc.2023.03.012","article-title":"Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced\/metastatic urothelial carcinoma by cisplatin-eligibility","volume":"41","author":"Morgans","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0007","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.7150\/jca.23162","article-title":"A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in germany","volume":"9","author":"Niegisch","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105680","article-title":"Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: A cohort study using routinely collected health data","volume":"91","author":"Tanaka","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0009","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2183\/pjab.98.026","article-title":"Clinical epidemiology and pharmacoepidemiology studies with real-world databases","volume":"98","author":"Yoshida","year":"2022","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0010","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0011","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/iju.15411","article-title":"Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan","volume":"31","author":"Kita","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0012","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1093\/oncolo\/oyad001","article-title":"Safety of immune checkpoint inhibitors in patients with advanced chronic kidney disease: a retrospective cohort study","volume":"28","author":"Tiu","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2024.09.020_bib0013","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/CMAR.S348899","volume":"14","author":"Miyake","year":"2022","journal-title":"Cancer Manag Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392400663X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392400663X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:43Z","timestamp":1762363963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392400663X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S107814392400663X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.020","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}